

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
24 February 2022 (24.02.2022)



(10) International Publication Number
WO 2022/040600 A1

(51) International Patent Classification:

A61K 31/403 (2006.01) C07D 209/02 (2006.01)
A61K 31/4164 (2006.01) C07D 235/04 (2006.01)
A61K 31/4184 (2006.01) C07D 235/06 (2006.01)

TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,
KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

— of inventorship (Rule 4.17(iv))

Published:

— with international search report (Art. 21(3))
— before the expiration of the time limit for amending the
claims and to be republished in the event of receipt of
amendments (Rule 48.2(h))

(21) International Application Number:

PCT/US2021/047015

(22) International Filing Date:

20 August 2021 (20.08.2021)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/068,870 21 August 2020 (21.08.2020) US

(71) Applicant: TERNIS PHARMACEUTICALS, INC.

[US/US]; 1065 E. Hillsdale Blvd., Suite 100, Foster City,
California 94404 (US).

(72) Inventors: ROMERO, F. Anthony; 1065 E. Hillsdale

Blvd., Suite 100, Foster City, California 94404 (US).
JONES, Christopher T.; 1065 E. Hillsdale Blvd., Suite
100, Foster City, California 94404 (US). FENAUX, Marti-
jn; 1065 E. Hillsdale Blvd., Suite 100, Foster City, Califor-
nia 94404 (US). REEVES, Corey; 1065 E. Hillsdale Blvd.,
Suite 100, Foster City, CA 94404 (US).

(74) Agent: SNYDER, Seth et al.; Morrison & Foerster LLP,

755 Page Mill Road, Palo Alto, California 94304-1018
(US).

(81) Designated States (unless otherwise indicated, for every

kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO,
DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN,
HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN,
KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD,
ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO,
NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW,
SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN,
TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every

kind of regional protection available): ARIPO (BW, GH,
GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ,
UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ,
TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK,
EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV,
MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM,

(54) Title: COMPOUNDS AS GLP-1R AGONISTS

(57) Abstract: The present application provides compounds that may be used as a glucagon-like peptide-1 receptors (GLP-1R) agonist, or stereoisomers, tautomers, or pharmaceutically acceptable salts of any of the foregoing. Also provided are pharmaceutical compositions containing such compounds, or stereoisomers, tautomers, or pharmaceutically acceptable salts of any of the foregoing. Methods of prepare these compounds and compositions and method of using them to treat or prevent a disease or a condition mediated by GLP-1R.

WO 2022/040600 A1